Clinical Trials Browser

Prostatic Neoplasms

NCT02057913 2020-07-23

VinCaP

Phase 2 Completed

22 enrolled

Genitourinary

Penile Neoplasms

NCT02665039 2019-10-08

VINGEM

Phase 2 Completed

62 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT01529411 2019-04-04

MAJA

Phase 2 Completed

86 enrolled

Genitourinary

Carcinoma, Carcinoma, Transitional Cell, Neoplasm Metastasis, Neoplasms

NCT00519831 2017-06-09

Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC

Phase 2 Terminated

18 enrolled 7 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00450515 2016-12-06

Vinflunine and Capecitabine in Treating Patients With Previously Treated Metastatic Breast Cancer

Phase 2 Withdrawn

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT01599013 2015-12-08

JASINT1

Phase 2 Completed

69 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis, Urogenital Neoplasms, Urologic Neoplasms, Renal Insufficiency

NCT00284180 2013-08-09

Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer

Phase 2 Completed

32 enrolled 6 charts

Breast

Breast Neoplasms

NCT00284154 2013-03-13

Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer

Phase 2 Completed

51 enrolled 10 charts

Thoracic

Lung Neoplasms, Recurrence, Carcinoma, Small Cell

NCT00251446 2012-05-11

A Phase II Single Arm Trial of Single-agent Vinflunine as Second-line Treatment of Advanced Non-Small Cell Lung Cancer

Phase 2 Completed

70 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00101608 2010-03-02

Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

Phase 2 Completed

150 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Kidney Neoplasms, Ureteral Neoplasms

Clinical Trials

Vinflunine in Hormone Refractory Prostate Cancer (HRPC)

VinCaP

VINGEM

MAJA

Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC

Vinflunine and Capecitabine in Treating Patients With Previously Treated Metastatic Breast Cancer

JASINT1

Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer

Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer

A Phase II Single Arm Trial of Single-agent Vinflunine as Second-line Treatment of Advanced Non-Small Cell Lung Cancer

Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium